Skip to main content
Terug
PHAR logo

Pharming Group N.V.

Datakwaliteit: 100%
PHAR
NASDAQ Healthcare Biotechnology
€ 16,23
▲ € 0,26 (1,63%)
Marktkapitalisatie: 1,08B
Ook genoteerd als PHGUF OTC
Dagbereik
€ 16,04 € 16,42
52-Weeksbereik
€ 7,50 € 21,34
Volume
12.720
50D / 200D Gem.
€ 17,05 / € 14,62
Vorige Slotkoers
€ 15,97

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E 442,3 0,2
P/B 4,6 3,0
ROE % 1,1 3,6
Net Margin % 0,8 3,8
Rev Growth 5Y % 12,7 9,7
D/E 0,5 0,2

Koersdoel Analisten

Hold
€ 39,50 +143.4%
Low: € 37,00 High: € 42,00
Forward K/W
96,32
Forward WPA
€ 0,17
WPA Groei (sch.)
+0,0%
Omzet Sch.
405,15M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,25
€ 0,23 – € 0,27
 602,42M 1
FY2029 € 0,49
€ 0,44 – € 0,53
 435,83M 1
FY2028 € 0,18
€ 0,16 – € 0,20
 353,79M 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-12 € 0,02 € 0,07 +366,7%
2025-11-06 € 0,05 € 0,10 +100,0%
2025-07-31 -€ 0,10 € 0,06 +160,0%
2025-05-08 -€ 0,25 -€ 0,22 +12,0%
2025-03-13 € 0,07 € 0,05 -28,6%
2024-10-24 € 0,01 -€ 0,02 -300,0%
2024-08-01 € 0,00 -€ 0,01 -400,0%
2024-05-08 € 0,01 -€ 0,19 -2000,0%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 12,73% annually over 5 years — strong growth
ROE of 1,07% is below average
Debt/Equity of 0,49 — conservative balance sheet
Generating 41,98M in free cash flow
P/E of 442,32 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,68%

Groei

Revenue Growth (5Y)
12,73%
Revenue (1Y)8,05%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
1,07%
ROIC3,52%
Net Margin0,76%
Op. Margin5,13%

Veiligheid

Debt / Equity
0,49
Current Ratio2,20
Interest Coverage0,91

Waardering

P/E Ratio
442,32
Forward P/E96,32
P/B Ratio4,56
EV/EBITDA64,77
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8,05% Revenue Growth (3Y) 14,41%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 12,73% Earnings Growth (5Y) -37,54%
Profitability
Revenue (TTM) 321,12M Net Income (TTM) 2,43M
ROE 1,07% ROA 0,57%
Gross Margin 87,90% Operating Margin 5,13%
Net Margin 0,76% Free Cash Flow (TTM) 41,98M
ROIC 3,52% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,49 Current Ratio 2,20
Interest Coverage 0,91
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 442,32 Forward P/E 96,32
P/B Ratio 4,56 P/S Ratio 3,35
PEG Ratio -3,67 Forward PEG N/A
EV/EBITDA 64,77 Fwd EV/EBITDA 22,54
Forward P/S 2,66 Fwd Earnings Yield 1,04%
FCF Yield 3,90%
Market Cap 1,08B Enterprise Value 1,07B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 321,12M 297,20M 245,32M 205,62M 198,87M
Net Income 2,43M -11,84M -10,55M 13,67M 16,00M
EPS (Diluted) 0,03 -0,17 -0,14 0,16 0,18
Gross Profit 282,27M 261,80M 220,10M 188,06M 177,73M
Operating Income 16,49M -8,62M -5,39M 18,23M 13,56M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 425,52M 399,99M 462,85M 425,80M 397,32M
Total Liabilities 189,68M 178,92M 244,07M 221,16M 204,40M
Shareholders' Equity 235,84M 221,06M 218,78M 204,64M 192,92M
Total Debt 115,78M 112,31M 171,55M 166,69M 161,76M
Cash & Equivalents 124,32M 54,94M 61,74M 207,34M 191,92M
Current Assets 254,88M 278,44M 316,34M 277,50M 249,44M
Current Liabilities 115,79M 73,80M 77,97M 59,70M 46,77M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#705 of 1049
36

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026